[1]
Xu, L.; Li, Y.; Yin, L.; Qi, Y.; Sun, H.; Sun, P.; Xu, M.; Tang, Z.; Peng, J. miR-125a-5p ameliorates hepatic glycolipid metabolism disorder in type 2 diabetes mellitus through targeting of STAT3. Theranostics, 2018, 8(20), 5593-5609.
[2]
Mao, Z.; Han, X.; Chen, D.; Xu, Y.; Xu, L.; Yin, L.; Sun, H.; Qi, Y.; Fang, L.; Liu, K.; Peng, J. Potent effects of dioscin against hepatocellular carcinoma through regulating TIGAR-mediated apoptosis, autophagy and DNA damage. Br. J. Pharmacol., 2019, 176(7), 919-937.
[3]
Zhao, L.; Tao, X.; Qi, Y.; Xu, L.; Yin, L.; Peng, J. Protective effect of dioscin against doxorubicin-induced cardiotoxicity via adjusting microRNA-140-5p- mediated myocardial oxidative stress. Redox Biol., 2018, 16, 189-198.
[4]
Zhao, L.; Qi, Y.; Xu, L.; Tao, X.; Han, X.; Yin, L.; Peng, J. Micro- RNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2. Redox Biol., 2018, 15, 284-296.
[5]
Hu, Y.; Tao, X.; Han, X.; Xu, L.; Yin, L.; Sun, H.; Qi, Y.; Xu, Y.; Peng, J. MicroRNA-351-5p aggravates intestinal ischemia/reperfusion injury via targeting MAPK13 and Sirt6. Br. J. Pharmacol., 2018, 175, 3594-3609.
[6]
Xu, L.; Li, Y.; Dai, Y.; Peng, J. Natural products for the treatment of type 2 diabetes mellitus: Pharmacology and mechanisms. Pharmacol. Res., 2018, 130, 451-465.
[7]
Yao, H.; Tao, X.; Xu, L.; Qi, Y.; Yin, L.; Han, X.; Xu, Y.; Zheng, L.; Peng, J. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway. Pharmacol. Res., 2018, 131, 51-60.
[8]
Si, L.; Xu, L.; Yin, L.; Qi, Y.; Han, X.; Xu, Y.; Zhao, Y.; Liu, K.; Peng, J. Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the AKT1 signaling pathway. Br. J. Pharmacol., 2017, 174(7), 553-568.
[9]
Zhang, Y.; Tao, X.; Yin, L.; Xu, L.; Xu, Y.; Qi, Y.; Han, X.; Song, S.; Zhao, Y.; Lin, Y.; Liu, K.; Peng, J. Protective effects of dioscin against cis-platin-induced nephrotoxicity via regulating miR-34a/Sirt1 signal pathway. Br. J. Pharmacol., 2017, 174(15), 2512-2527.
[10]
Zhang, Y.; Xu, Y.; Qi, Y.; Xu, L.; Song, S.; Yin, L.; Tao, X.; Zhen, Y.; Han, X.; Ma, X.; Liu, K.; Peng, J. Protective effects of dioscin against doxorubicin-induced nephrotoxicity via adjusting FXR-mediated oxidative stress and inflammation. Toxicology, 2017, 378, 53-64.
